D
iabetes mellitus-associated impaired wound healing severely affects life quality of patients with diabetes mellitus leading to prolonged hospitalization and lower limb amputations. 1, 2 Diabetes mellitus causes ≈50% of all nontraumatic amputations of the lower extremities worldwide and >80 000 procedures are performed annually. 3 The life-time risk of amputation in patients with diabetes mellitus is 10% to 15%, which is 10 to 30× higher in comparison with the general population. [4] [5] [6] Multifactorial pathways including peripheral arterial disease (PAD), peripheral neuropathy, chronic inflammatory state, and altered cellular functions influence the development of diabetic chronic wounds. 7, 8 PAD is present in approximately one-half of all patients with foot ulcers and accounts for chronic wounds because of insufficient perfusion. 9 Leg amputation because of atherosclerotic PAD corresponds to a mortality rate of ≈30% and a 5-year prognosis with survival rates of <5 years. 6, 10, 11 Persistent inflammation is a hallmark of patients with chronic diabetic wounds as the circulating cytokine levels in patients with diabetes mellitus with nonhealed foot ulcers remain closer to that of the active diabetic foot ulcer patients. 7 MicroRNAs (miRNAs/miRs), highly conserved small RNAs (≈22 nucleotides), are master regulators of diverse aspects of cellular functions acting mainly via translational inhibition after recognition binding of 3′untranslated region of mRNA transcripts. [12] [13] [14] MiRNAs present in body fluids including blood have demonstrated their potential as novel biomarkers of diabetes mellitus and cardiovascular disorders. [15] [16] [17] These extracellular miRNAs mainly originate by cellular secretion (exosomes, microparticles) or shedding of apoptotic bodies. 16 Protective packaging of miRNAs in microvesicles, protein complexes (nucleophosmin, Ago-2), or lipoproteins (low-density lipoprotein or high-density lipoprotein) physically shields circulating miRNAs from endogenous RNAses and renders remarkable stability. 18 Deregulation of plasma miRNAs in diabetes mellitus has been reported 16 ; however, effects of diabetes mellitus-associated impairment of tissue repair on diabetic miRNA signatures are unknown. We therefore investigated circulating miRNAs patterns in patients with diabetes mellitus-associated PAD with or without chronic wounds compared with patients with diabetes mellitus without PAD or healthy controls. We further explored the mechanism of inflammation-driven secretion of diabetic miRNAs and their potential paracrine role in cellular interactions to control cellular functions essential for tissue repair.
Materials and Methods
Detailed Materials and Methods are available in the online-only Data Supplement.
Study Population
The study was confirmed by the local Ethical Committee and all patients received/signed written informed consent. The study cohort included 61 patients, diagnosed with type 2 diabetes mellitus (T2DM) according to the current American Diabetes Association/ European Association for the Study of Diabetes guidelines, from inpatients at the Heart and Diabetes Center North Rhine-Westphalia in Bad Oeynhausen and 20 body mass index-matched healthy controls (characteristics in Table 1 ). Patients with PAD history or current PAD were considered as PAD positive and wounds were defined as chronic if they persisted >2 weeks without healing tendency on standard treatment.
All antidiabetic drugs, antiplatelet agents, antihypertensive, and lipid-lowering agents were allowed to resemble real hospital/life situation ( Table 1) . Standardized examinations included clinical biochemistry and detailed investigation of comorbidity following current medical guidelines.
Plasma Total RNA Isolation, miRNA Profiling, and Expression Validation
Total RNA was isolated from plasma and wound fluid samples using miRNeasy kit (Qiagen, Hilden). Affymetrix miRNA array was performed on total RNA pooled from 23 diabetic controls or 17 patients with diabetes mellitus with PAD and chronic wounds, respectively, and data were analyzed as described. 15 The microarray data were submitted to Gene Expression Omnibus database and referenced with Figure 1A ). To analyze whether changes in miRNA concentrations were because of underlying PAD or wound-associated inflammatory conditions, levels of miRNAs were further validated in individual plasma samples from an entire cohort comprising 26 patients with PAD and associated impaired wound healing, 12 patients with PAD alone, 23 diabetic control subjects without PAD or chronic wounds, and 20 healthy individual control subjects. Patient's characteristics are given in Table 1 . Based on the level of regulation and their reported functional roles, 2 miRNAs were selected for further validation: (1) derived from miRNA screens, which is expressed in endothelial cells and platelets and (2) miR-200b: an inflammation-regulated modulator of diabetic skin wound healing. 20, 21 Indeed, in the candidate validation experiments, plasma levels of circulating miR-191 and miR-200b were significantly decreased 3-to 6-fold in type 2 diabetic subjects (n=23) versus healthy controls (P<0.05; n=20; Figure 1B ). Presence of PAD alone with diabetes mellitus did not affect plasma levels of these miRNAs. In strong contrast, an increase ≤2-to 3-fold was observed in miR-191 and miR-200b levels in patients with the presence of PAD and chronic wounds (P<0.05; n=26; Figure 1B ).
Diabetes-Associated Circulating MiRNA Pattern Correlates With Inflammatory Markers and Wound Size
Patients with diabetes mellitus with impaired wound healing are prone to systemic inflammation. Indeed, among patients with diabetes mellitus, significantly higher plasma levels of C-reactive protein were observed in the presence of chronic wounds (4.21±1.13 mg/dL; n=26) compared with patients without wounds (0.49±0.11 mg/dL; n=23; P=0.0002) or with PAD only (0.50±0.20 mg/dL; n=12; P=0.006; Table 1 ). In addition, elevated blood leukocyte counts in patients with diabetes mellitus with chronic wounds compared with other groups (P<0.05; Table 1 ) indicated an aggravated inflammatory environment. Circulating miR-191 levels significantly correlated with C-reactive protein (r=0.333; P=0.009), monocyte counts (r=0.342; P=0.009), and wound size (r=0.416; P=0.035), whereas miR-200b positively correlated with C-reactive protein levels (r=0.329; P=0.011) and showed a strong correlation with miR-191 levels (Tables 2 and 3 ).
The proinflammatory state in patients with T2DM with impaired wound healing was further characterized by multiplex protein assays to screen plasma cytokine and chemokine levels. This approach identified plasma levels of 13 of 20 tested cytokines, namely interleukin (IL)-1b, IL-2, IL-5, IL-6, IL-10, interferon-γ, tumor necrosis factor-α, IL-18; chemokines C-X-C motif ligand 8 (IL-8) and C-C motif ligand 3 (macrophage inflammatory protein-1α) as well as the growth factors fibroblast growth factor, vascular endothelial growth factor, and hepatocyte growth factor to be significantly increased in patients with T2DM having abnormal wound healing compared with no wound patients (Figure 2A ). Significant correlations were observed between circulating miR-191 levels and IL-1b, platelet-derived growth factor-bb and MIF, whereas miR-200b levels correlated with MIF and platelet-derived growth factor-bb in an overall diabetic cohort ( Table 2) . A potential reason of increased plasma miRNA levels in patients with chronic wounds could be a local overproduction and release of miRNAs within the wounds. To test this hypothesis, we measured inflammatory cytokines and miRNAs directly in wound fluid versus peripheral blood obtained from the same patients. Patients with diabetes mellitus with chronic wounds exhibited extremely high extracellular cytokine levels in wound fluids, indicating an inflammatory environment of the wounds ( Figure 2B ). In contrast, levels of miR-191 in wound fluids were lower (almost 2 Ct cycles, P=0.06) in comparison with corresponding plasma samples ( Figure 2C) . Hence, the inflammatory cells accumulated in the local wound site might not be serving as an active source to release miR-191 and to elevate the circulating miR-191 concentrations.
Endothelial and Platelet Secretions of T2DM-Associated MiRNAs Increase Under Inflammatory Settings
To explain inflammation-mediated increase in plasma miRNA concentrations in patients with T2DM with chronic wounds, we hypothesized that various inflammatory cytokines could trigger direct miRNA release from vascular endothelial cells or platelets. We thus mimicked a proinflammatory environment as observed in the plasma samples of patients with diabetes mellitus with chronic wounds by stimulating endothelial cells or isolated human platelets with inflammatory cytokines/chemokines which were significantly elevated in type 2 diabetes mellitus+PAD+chronic wounds group. Indeed, exposure of endothelial cells to the various concentrations of cytokines/chemokines (IL-6, CXCL8 , hepatocyte growth factor, VEGF, or tumor necrosis factor-α) alone (data not shown) or in combination increased endothelial-secreted miR-191 levels ≤3-fold (P<0.05) as measured in cell culture supernatants ( Figure 3A) . Likewise, miR-200b release was also increased from washed human platelets on cytokine stimulation ( Figure 3B ).
Paracrine Functional Effects of Circulating Diabetic miRNAs
Further studies were performed to investigate the influence of chosen miRNAs on cellular functions involved in dermal wound healing. We performed either gain or loss of functional Figure 4C-4E ). ZO-1 is a multiple domain scaffold protein with a reported role in cell to cell adhesion, maintenance of tissue structure and hence modulates angiogenesis and cellular migration during the tissue remodeling and repair. 22 The binding of miR-191 to 3′untranslated region of ZO-1 transcript was confirmed by reduced luciferase reporter activity after miR-191 overexpression ( Figure 4D ). In line, ZO-1 knockdown showed a similar phenotype as that of miR-191 overexpression in dermal cells. ZO-1 silencing rescued the angiogenic effect of miR-191 inhibitor treatments of dermal endothelial cells ( Figure 4A and 4B ). This suggests miR-191 to function at least in part through its direct target ZO-1.
To study whether miRNAs secreted from endothelial cells under proinflammatory settings would affect dermal fibroblast biology, we performed coculture assays ( Figure 5A, scheme) . Indeed, coculturing dermal fibroblasts with miRNA-secreting endothelial cells (under inflammatory stimuli conditions) increased intracellular fibroblast concentration of miR-191 compared with fibroblasts cultured without endothelial cells ( Figure 5B ). In addition, fibroblasts cocultured with endothelial cells under inflammatory settings showed inverse correlation between expression levels of miR-191 and its target ZO-1 suggesting functional effects of miRNA exchange ( Figure 5B endothelial cells and subsequent paracrine functions of miRNA in dermal cells on their uptake is depicted in Figure 6 .
Discussion
Altered levels of circulating miRNAs, which can be detected in body fluids, for example, blood and urine, have been linked to various pathophysiological situations including diabetes mellitus. 16 A recent clinical study demonstrated biomarker potential of circulating miR-126 in T2DM. 16 However, plasma miRNA regulation in diabetes mellitus-associated impaired wound healing was not addressed previously. Our study reports a differential signature pattern of circulating miRNAs in patients with T2DM depending on the presence or absence of chronic wounds. A thorough investigation of circulating cytokines suggests that inflammation underlying abnormal wound healing is a key factor to influence plasma miRNA levels. miR-191 is a stress-sensitive miRNA that has been extensively studied in cancer pathologies and reduced levels of this miRNA are shown in connection with diabetes mellitus. 16, 23 Modulation in miR-191 expression regulates apoptosis, cell proliferation, migration, and cell cycle under various pathological settings. 23 Interestingly, altered plasma levels of endothelial-rich miRNAs, for example, miR-191 or miR-126 is reported to reflect underlying endothelial dysfunction in diabetes mellitus. 16 miR-191 is coexpressed with the miR-191/425 cluster which is highly conserved in higher eukaryotes 24 and our plasma miRNA profiles also confirm a unidirectional changes in circulating plasma levels of both clustered miRNAs from patients with diabetes mellitus with impaired wound healing compared with diabetics with no chronic wound. miR-200b is a known hypoxia-sensitive miRNA that induces angiogenesis in hypoxic dermal cells. 20, 21 Under inflammatory stress, miR-200b is upregulated in endothelial cells and targets angiogenic genes VEGF2. 21 In diabetic skin wounds, the expression of miR-200b remains higher compared with nondiabetic wounds and the silencing of miR-200b supports wound angiogenesis. 21 In line, our study not only confirms inflammatory regulation of miR-200b in vitro and in plasma of patients with diabetes mellitus but also extends to the regulation of another miRNA candidate miR-191 in similar pathological settings. Positive correlations between plasma levels of both miR-191 and miR-200b to plasma C-reactive protein and cytokine levels confirm underlying inflammatory conditions to influence plasma miRNA levels. miRNAs circulating in blood plasma represent a pool of miRNAs secreted by vascular cells, mainly endothelial cells, platelets, and challenged immune cells in the form of vesicles, for example, exosomes or apoptotic bodies. [25] [26] [27] The miRNA patterns in body fluids including plasma therefore depend on several factors of cellular origin, presence of stressors, pathological conditions, or drug treatment. 16, 28 In our study, differences in miR-191 levels were also observed between wound exudates versus plasma as the local composition of cells secreting these miRNAs varies; for example, the local wound environment is rich in leukocytes and cellular debris. Thus, the low levels of miR-191 in wound fluid indicates a minor role of wound accumulated inflammatory cells; however, inflammation-sensitive endothelial cells or platelets might be the major contributors to the systemic miRNA increase in patients with diabetes mellitus with abnormal wound healing. Vascular endothelial cells secrete miRNAs in the form of exosomes or apoptotic bodies enabling their transport to the distant pathological targets, as evident form transport of miR-126 to the atherosclerotic lesions which indicates to a unique paracrine-signaling function of miRNAs during atherosclerosis. 27 Differences in circulating miRNAs in patients with diabetes mellitus with impaired wound healing may arise because of altered secretion of miRNAs from inflammation-stimulated endothelial cells and apparently our in vitro observations prove miR-191 release from endothelial cells under proinflammatory stress. Pertaining to the miRNA secretory capacity of platelets and increased atherothombotic events in patients with diabetes mellitus, platelets might be another prominent source of circulating miRNAs in plasma. 29 In fact, platelets exposed to proinflammatory conditions release significantly higher amount of miR-200b compared with unstimulated platelets. Most of the advanced patients with diabetes mellitus with PAD and abnormal wound healing were prescribed antiplatelet treatment to lower the risk of atherosclerotic and atherothrombotic events, which could suppress the miRNA secretion from platelets. 26, 28 However, an increased proportion of reticulated platelets with more secretory capacity despite of high platelet turnover rate 30, 31 suggests a potential involvement of platelet-secreted miRNAs in the diabetic plasma pool.
Current evidences in the literature support the existence of extracellular miRNAs-mediated cross-talks between different types of cells under various pathological conditions that may exert paracrine effects on cellular signaling and functions. 32, 33 In line with previous reports, we observed that dermal fibroblasts and dermal microvascular endothelial cells can take up vascular endothelial-secreted miR-191 leading to high miRNA levels in these cells with detrimental cellular effects such as impaired migratory or angiogenic responses and increased apoptosis. Nevertheless, miR-191 target gene ZO-1 was inversely regulated in cocultured fibroblasts as well as in dermal endothelial cells or fibroblasts on miR-191 overexpression. The expression of ZO-1 is reportedly increased on the locomotive surface of cells during wound healing. 34 Reduced expression of ZO-1 parallel to miR-191 upregulation as seen in lipopolysaccharide or cytokine challenged dermal fibroblasts when cocultured with endothelial cells therefore could attenuates cellular migration. This was evident by delayed wound closure on miR-191 overexpression not only in fibroblasts but also in dermal microvascular endothelial cell. In endothelial cells, ZO-1 is a mediator of angiogenesis and its deficiency leads to defects in vascular development with impaired formation of vascular trees important for tissue organization and remodeling. 35 The paracrine regulation of ZO-1 in dermal cells mediated via miR-191 uptake potentially contributes in slowing down of the tissue repair process commonly observed in patients with diabetes mellitus.
Conclusions
Our study presents novel data on differential patterns of circulating plasma miRNAs in patients with diabetes mellitus with associated impaired wound healing. We show for the first time that inflammation underlying nonhealing wounds mediate endothelial miR-191 secretion which is also correlated with the clinical findings of increased plasma levels of miR-191 in diabetic foot ulcer patients. Furthermore, our results suggest a subsequent paracrine mechanism involving miR-191 uptake and modulation of target genes ZO-1 in recipient dermal cells to compromise the cellular functions essential for tissue repair. 
